secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001437749-25-034846
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva reports Q3 net loss of $4.0M; cash $13.2M; pre-NDA meeting with FDA on track
--------------------------------------------------------------------------------

- Net loss of $4.0M ($0.06 per share) for Q3 2025, compared to $8.4M ($0.25) in Q3 2024.
- Cash and cash equivalents totaled $13.2M as of September 30, 2025.
- Pre-NDA meeting with FDA planned for Q4 2025; NDA submission for schizophrenia targeted for Q2 2026.
- European patent granted covering use of brilaroxazine for treatment of pulmonary fibrosis.
- Closed public equity offering with gross proceeds of $9.0M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925034846/0001437749-25-034846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925034846/rvph20251103_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer